Qiagen refinances 2021 convert with new $500m bond

Aidan Gregory

December 10, 2020 12:45 pm

Qiagen_PA_575_375 — 08 September 2020, North Rhine-Westphalia, Hilden: Employees work in protective suits in a laboratory of the biotech company Qiagen. With financial support from the state of North Rhine-Westphalia, the biotech company Qiagen is expanding its production capacities for corona tests at its Hilden site near Düsseldorf. Qiagen will receive 18.3 million euros for the expansion of its laboratory diagnostics production facilities. Photo: Fabian Strauch/dpa | Fabian Strauch/DPA/PA Images

Qiagen, the Dutch diagnostics company, has launched the sale of a new convertible bond to refinance the unwinding of an older bond, set to mature in 2021.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login

✔ 4,000 annual insights
✔ 700+ notes and long-form analyses
✔ 4 capital markets databases
✔ Daily newsletters across markets and asset classes
✔ 2 weekly podcasts

Topics

Germany Health and Biotech The Netherlands Equity Europe EMEA SRI Equity-Linked

AG

Aidan Gregory